HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1. (Q40369481)

19 September 2017

title

HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1. (English)

1 reference

19 September 2017

4

Britta Wahren

1 reference

19 September 2017

Elizaveta Starodubova

series ordinal

1

object named as

Elizaveta Starodubova

1 reference

19 September 2017

6

Maria Isaguliants

1 reference

19 September 2017

5

Vadim Karpov

1 reference

19 September 2017

Andreas Boberg

2

1 reference

19 September 2017

Elena V Kashuba

series ordinal

3

1 reference

19 September 2017

language of work or name

English

0 references

publication date

18 August 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

24

1 reference

19 September 2017

issue

21

1 reference

19 September 2017

page(s)

4541-4547

1 reference

Antigen processing by the proteasome

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

The specificity of proteasomes: impact on MHC class I processing and presentation of antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Degradation of HIV-1 integrase by the N-end rule pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

The lethal phenotype observed after HIV-1 integrase expression in yeast cells is related to DNA repair and recombination events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

HIV-1 Nef disrupts antigen presentation early in the secretory pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Transmission of HIV-1 drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Mutations conferring drug resistance affect eukaryotic expression of HIV type 1 reverse transcriptase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

The N-end rule: functions, mysteries, uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Human monocytes possess a serine protease activity capable of degrading HIV-1 reverse transcriptase in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Proteasome inhibitors: valuable new tools for cell biologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Cytotoxic T lymphocytes generation capacity in early life with particular reference to HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Effector HIV‐specific cytotoxic T‐lymphocyte activity in long‐term nonprogressors: Associations with viral replication and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Degradation of ornithine decarboxylase in mammalian cells is ATP dependent but ubiquitin independent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Attenuation of green fluorescent protein half-life in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

Early and late cytotoxic T lymphocyte responses in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2005.08.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.08.020

1 reference

19 September 2017

1 reference